Cardiovascular research has improved care and clinical outcomes, including for patients in emergency and critical care settings. Over this same time frame, the spectrum of illnesses within critical cardiology care (CCU) units has changed markedly. In its original concept, in the 1940s the CCU was designed as dedicated coronary care units (CCUs), for the rapid recognition and resuscitation of arrhythmia. Today, the modern CCU has evolved into a critical care environment that reflects changing demographics in the population served within these CCU—namely, a decreasing number of acute coronary patients and an increasing burden of cardiogenic shock, heart failure, primary non cardiac diagnoses, and patients with numerous comorbidities and multisystem organ dysfunction. The changing profiles represent future clinical and research opportunities.
Large prospective clinical trials focused on cardiac critical care patients have been lacking. In addition, data supporting improvement in clinical outcomes in intensive care units existed only for general medical and surgical critical care units with little guidance existing to support the development of best-practice principles specific to the CCU. Therefore, given the heterogeneity in the care of critically ill cardiac patients, research on quality improvement must address the epidemiology of modern CCU by evaluating large prospective registries and enrolling multiple centers in clinical trials.
Led by an international team of subject experts, the editorial team welcome all manuscript types including original research, case reports, reviews and method type manuscripts. The Topic Editors welcome manuscripts approaching observational and review data in critical care epidemiology, cardiogenic shock epidemiology, inotropes, and vasopressors use in cardiogenic shock, use of ventilatory support in cardiogenic shock and cardiogenic critical care units, biomarkers in cardiogenic shock .
Conflicts of Interest
- Dr R.Furtado reports research grants and personal fees from AstraZeneca, Bayer, Biomm and Servier; and research grants from Pfizer, EMS, Aché, CytoDin, Brazilian Ministry of Health, University Health Network (received from his institution), and Lemann Foundation Reseach Fellowship.
-Dr A.Fagundes reports research grants and personal fees from MERCK SHARP DOHME FARMACÊUTICA LTDA, Boehringer Ingelheim, Lemann Foundation Reseach Fellowship.
Cardiovascular research has improved care and clinical outcomes, including for patients in emergency and critical care settings. Over this same time frame, the spectrum of illnesses within critical cardiology care (CCU) units has changed markedly. In its original concept, in the 1940s the CCU was designed as dedicated coronary care units (CCUs), for the rapid recognition and resuscitation of arrhythmia. Today, the modern CCU has evolved into a critical care environment that reflects changing demographics in the population served within these CCU—namely, a decreasing number of acute coronary patients and an increasing burden of cardiogenic shock, heart failure, primary non cardiac diagnoses, and patients with numerous comorbidities and multisystem organ dysfunction. The changing profiles represent future clinical and research opportunities.
Large prospective clinical trials focused on cardiac critical care patients have been lacking. In addition, data supporting improvement in clinical outcomes in intensive care units existed only for general medical and surgical critical care units with little guidance existing to support the development of best-practice principles specific to the CCU. Therefore, given the heterogeneity in the care of critically ill cardiac patients, research on quality improvement must address the epidemiology of modern CCU by evaluating large prospective registries and enrolling multiple centers in clinical trials.
Led by an international team of subject experts, the editorial team welcome all manuscript types including original research, case reports, reviews and method type manuscripts. The Topic Editors welcome manuscripts approaching observational and review data in critical care epidemiology, cardiogenic shock epidemiology, inotropes, and vasopressors use in cardiogenic shock, use of ventilatory support in cardiogenic shock and cardiogenic critical care units, biomarkers in cardiogenic shock .
Conflicts of Interest
- Dr R.Furtado reports research grants and personal fees from AstraZeneca, Bayer, Biomm and Servier; and research grants from Pfizer, EMS, Aché, CytoDin, Brazilian Ministry of Health, University Health Network (received from his institution), and Lemann Foundation Reseach Fellowship.
-Dr A.Fagundes reports research grants and personal fees from MERCK SHARP DOHME FARMACÊUTICA LTDA, Boehringer Ingelheim, Lemann Foundation Reseach Fellowship.
